Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
26 sept. 2024 08h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
24 sept. 2024 08h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
PetVivo Taps Top Sales Executive, Skylor Walker, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
16 sept. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor...
PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV
12 sept. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, was recently...
PetVivo Teams with Orthobiologic Innovations for Clincial Research and Product Commercialization
27 août 2024 08h00 HE
|
PetVivo Holdings, Inc.
Orthobiologic President & CEO, Sherman O. Canapp, Jr. and Director of Diagnositcs and Education, Debra Cannap, Join PetVivo Advisory Board MINNEAPOLIS, MN, & Annapolis Junction, MD, US,...
Anthony Germinaro Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
19 août 2024 10h10 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
PetVivo Reports Reports Fiscal Q1 2025 Results
14 août 2024 16h25 HE
|
PetVivo Holdings, Inc.
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical...
Crescent Innovations reports strong interest in asset sale
13 août 2024 08h30 HE
|
Crescent Innovations Inc.
Crescent Innovations Inc. reports that activity surrounding sale of its joint, bone and skin repair technology remains strong even at this late date.
Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
12 août 2024 13h52 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
PetVivo Sets Fiscal First Quarter 2025 Conference Call for Wednesday, August 14 at 5:00 p.m. ET
08 août 2024 10h25 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 08, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and...